SALL4 and cancer: For the cancer recurrence, considering the available 4 studies [16, 23, 25, 28] and the 17 TCGA cohorts, a similar result was obtained confirming a worse prognostic role of SALL4+ (HR=1.52; 95% CI: 1.22-1.89, p=0.0002; I2=69%) (Figure 2b).